> Detailanzeige

Busch, Elena [Verfasser:in]; Ahadova, Aysel [Verfasser:in]; Kosmalla, Kosima [Verfasser:in]; Bohaumilitzky, Lena [Verfasser:in]; Pfuderer, Pauline L. [Verfasser:in]; Ballhausen, Alexej [Verfasser:in]; Witt, Johannes [Verfasser:in]; Wittemann, Jan-Niklas [Verfasser:in]; Bläker, Hendrik [Verfasser:in]; Holinski-Feder, Elke [Verfasser:in]; Jäger, Dirk [Verfasser:in]; von Knebel Doeberitz, Magnus [Verfasser:in]; Haag, Georg Martin [Verfasser:in]; Kloor, Matthias [Verfasser:in]

Beta-2-microglobulin Mutations Are Linked to a Distinct Metastatic Pattern and a Favorable Outcome in Microsatellite-Unstable Stage IV Gastrointestinal Cancers

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Beta-2-microglobulin Mutations Are Linked to a Distinct Metastatic Pattern and a Favorable Outcome in Microsatellite-Unstable Stage IV Gastrointestinal Cancers
  • Beteiligte: Busch, Elena [Verfasser:in]; Ahadova, Aysel [Verfasser:in]; Kosmalla, Kosima [Verfasser:in]; Bohaumilitzky, Lena [Verfasser:in]; Pfuderer, Pauline L. [Verfasser:in]; Ballhausen, Alexej [Verfasser:in]; Witt, Johannes [Verfasser:in]; Wittemann, Jan-Niklas [Verfasser:in]; Bläker, Hendrik [Verfasser:in]; Holinski-Feder, Elke [Verfasser:in]; Jäger, Dirk [Verfasser:in]; von Knebel Doeberitz, Magnus [Verfasser:in]; Haag, Georg Martin [Verfasser:in]; Kloor, Matthias [Verfasser:in]
  • Erschienen: Lausanne: Frontiers Research Foundation, [2023]
  • Erschienen in: Frontiers in oncology ; 11, (2021)
  • Sprache: Englisch
  • Schlagwörter: B2M mutation ; metastatic pattern ; immune checkpoint blockade ; prognosis ; MSI cancer ; therapy response
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: Immune checkpoint blockade (ICB) shows remarkable clinical effects in patients withmetastatic microsatellite-unstable (MSI) cancer. However, markers identifying potentialnon-responders are missing. We examined the prevalence of Beta-2-microglobulin (B2M)mutations, a common immune evasion mechanism, in stage IV MSI gastrointestinalcancer and its influence on metastatic pattern and patients’ survival under ICB. Twentyfivepatients with metastatic, MSI gastrointestinal adenocarcinoma were included.Eighteen patients received ICB with pembrolizumab and one patient with nivolumab/ipilimumab. Sequencing was performed to determine B2M mutation status. B2Mmutations and loss of B2M expression were detected in 6 out of 25 stage IV MSIcancers. B2M mutations were strongly associated with exclusively peritoneal/peritonealand lymph node metastases (p=0.0055). However, no significant differences in therapyresponse (25% vs. 46.6%, p>0.99) and survival (median PFS: 19.5 vs 33.0 months,p=0.74; median OS 39 months vs. not reached, p>0.99) were observed between B2Mmutantand B2M-wild type tumor patients. Among metastatic MSI GI cancers, B2Mmutanttumors represent a biologically distinct disease with distinct metastatic patterns.To assess ICB response in B2M-mutant MSI cancer patients, future studies need toaccount for the fact that baseline survival of patients with B2M-mutant MSI cancer may belonger than of patients with B2M-wild type MSI cancer.
  • Zugangsstatus: Freier Zugang
  • Rechte-/Nutzungshinweise: Namensnennung (CC BY)